4-AcO-DPT Stats & Data
CCCN(CCC)CCc1cnc2cccc(OC(C)=O)c12KRUGABVNKKKCJN-UHFFFAOYSA-NReceptor Profile
Receptor Actions
Effect Profile
Curated + 2 ReportsModerate visuals with mild body load and headspace
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Cross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Too few reports for a chart: gender is known from 5 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?
- Male 3 of 5
- Not Specified 2 of 5
Age Distribution
Reports Over Time
Real-World Dose Distribution
ErowidFrom 5 of 5 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.
Insufflated (n=5)
Common Combinations
Most co-occurring substances, as a share of all 5 reports filed under 4-AcO-DPT
Too few reports for bars: these combinations come from 5 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
- THC 3 of 5
Form / Preparation
Most common forms and preparations, as a share of the 4 reports that give one
Too few reports for bars: these forms come from 4 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
- Powder / Crystals 4 of 4
References
Data Sources
Cited References
- Erowid: 4-AcO-DPT Vault
- Grynkiewicz et al. Human Hepatocyte Metabolism of 4-AcO-DiPT (2022)
- Investigation of the Structure–Activity Relationships of Psilocybin Analogues - PMC
- Malaca et al. Toxicology and Analysis of Psychoactive Tryptamines (2020)
- Bluelight Nervewing: . 4-AcO-DPT Experience Report
- Erowid: 4-AcO-DPT Vault – Dosage & Effects
- Grynkiewicz et al. Human Hepatocyte Metabolism of 4-AcO-DPT (2022)